NIH rare diseases coordinator
Executive Summary
HHS Assistant Secretary for Health Mason announced at May 3 meeting on rare diseases that Stephen Groft, formerly with FDA's Office of Orphan Products, is being appointed coordinator for rare disease activities at the National Institutes of Health. Groft will work with a network of about 20 staff members who have been designated as focal points for rare disease research within NIH, Mason said. Groft also will work with FDA on developing implementation plans for recommendations made by the National Commission on Orphan Diseases.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.